Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04854096 · ClinicalTrials.gov registry record · Phase 2
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
A Phase 2 study, sponsored by NS Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04854096: Clinical Trial Phase 2 study, sponsored by NS Pharma.
NCT04854096 is a Phase 2 study that was terminated before completion, run by NS Pharma. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04854096, a Phase 2 study, was terminated before completion, sponsored by NS Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-risk MF according to the Dynamic International Prognostic Scoring System (DIPSS).
Primary Outcome
Proportion of subjects who achieve ≥35% reduction in spleen volume from baseline compared to Week 24 as measured by MRI (or by CT for applicable subjects)
Interventions
- DRUG NS-018
- DRUG Best Available Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2024-05-16 |
| Phase | Phase 2 |
Why NCT04854096 stopped before completion
NCT04854096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which NS-018 is the first listed.
NCT04854096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04854096 about?
NCT04854096 is a clinical study titled "Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis". This study will enroll male and female subjects who are 18 years of age or older with Primary Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia Myelofibrosis with severe thrombocytopenia (platelet count \<50,000/µL) including subjects with intermediate-2 or high-...
What is the current status of trial NCT04854096?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2023-01-31. Estimated completion is 2024-05-16.
What interventions are being tested in trial NCT04854096?
The interventions under investigation include: NS-018 (DRUG), Best Available Therapy (DRUG).
Who is sponsoring clinical trial NCT04854096?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04854096's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI